

1. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. Tsurumi Y, Nagashima H, Ichikawa K, Sumiyoshi T, Hosoda S. *J Am Coll Cardiol* 1995;26:1242-1250
2. The role of cadherin-catenin-cytoskeleton complex in angiogenesis: antisense oligonucleotide of plakoglobin promotes angiogenesis in vitro, and protein kinase C enhances angiogenesis through the plakoglobin signaling pathway. Nagashima H, Okada M, Hidai C, Hosoda S, Kasanuki H, Kawana M. *Heart Vessels* 1997;Suppl 12:110-112
3. Functional activity of the CFTR Cl channel in human myocardium. Yajima T, Nagashima H, Tsutsumi-Sakai R, Hagiwara N, Hosoda S, Quertermous T, Kasanuki H, Kawana M. *Heart Vessels* 1997;12:255-261
4. Novel mechanism associated with an increased cardiac arrhythmia: Defective protein trafficking by the mutant HERG (G601S) potassium channel. Furutani M, Hagiwara N, Trudeau MC, Nagashima H, Kasanuki H, Robertson GA, Matsuoka R. *Circulation* 1999;99:2290-2294.
5. α -catenin-deficient F9 cells differentiation into signet ring cells. Maeno Y, Moroi S, Nagashima H, Tsukita S, Nagafuchi A. *Am J Pathol* 1999; 154:1323-1328.
6. Congestive heart failure after peripheral blood stem cell transplantation: Role of cytokines. Nagashima H, Kawashiro-Hirata N, Imamura K, Shimamoto K, Kawana M, Kasanuki H. *Circ J.* 2000;64:382-384
7. Cardiac-specific overexpression of cyclin-dependent kinase 2 increases smaller mononuclear cardiac myocytes. Liao HS, Kang PM, Nagashima H, Yamasaki N, Izumo S. *Circ Res.* 2000;88:443-450
8. Malfunction of a Hancock bioprosthesis in the mitral position 24 years after initial implantation. Niinami H, Naito Y, Koyanagi H, Nagashima H, Kasanuki H. *J Heart Valve Dis.* 2000;9:810-812
9. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Teno S, Uto Y, Nagashima H, Iwamoto Y, Omori Y, Takizawa T. *Diabetes Care* 2000;23:1401-1406
10. KL-6 as a potential new marker for amiodarone-induced pulmonary toxicity. Endoh Y, Hanai R, Uto K, Uno M, Nagashima H, Narimatsu A, Takizawa T, Onishi S, Kasanuki H. *Am J Cardiol* 2000;86:229-231
11. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Nagashima H, Sakomura Y, Aoka Y, Uto K, Kameyama K, Ogawa M, Aomi S, Koyanagi H, Ishizuka N, Naruse M, Kawana M, Kasanuki H. *Circulation.* 2001;104:I282-I287

12. An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Production of Matrix Metalloproteinase-9 in Human Abdominal Aortic Aneurysm Wall. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. *J Vasc Surg* 2002;36:158-163
13. An Angiotensin-converting enzyme inhibitor, but not an angiotensin II type 1 receptor blocker, prevents β -aminopropionitrile monofumarate-induced aortic dissection in rats. Nagashima H, Uto K, Sakomura Y, Aoka Y, Sakuta A, Aomi S, Hagiwara N, Kawana M, Kasanuki H. *J Vasc Surg* 2002;36:818-23
14. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Omori H, Nagashima H, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. *Br J Clin Pharmacol* 2002;54:395-399
15. Expression of peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells is upregulated in cystic medial degeneration of annuloaortic ectasia in Marfan syndrome. Sakomura Y, Nagashima H, Aoka Y, Uto K, Sakuta A, Aomi S, Kurosawa H, Nishikawa T, Kasanuki H. *Circulation*. 2002; 106:I259-I263.
16. Therapeutic value of statins for vascular remodeling. Nagashima H, Kasanuki H. *Curr Vasc Pharmacol* 2003;1:273-279
17. FGF-1 enhanced cardiogenesis in differentiating embryonal carcinoma cell cultures, which was opposite to the effect of FGF-2. Hidai C, Masako O, Ikeda H, Nagashima H, Matsuoka R, Quertermous T, Kasanuki H, Kokubun S, Kawana M. *J Mol Cell Cardiol*. 2003;35:421-425
18. Matrix metalloproteinase-2 is suppressed by trapidil, a CD40-CD40L pathway inhibitor, in human abdominal aortic aneurysm wall. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Kasanuki H. *J Vasc Surg*. 2004;39: 447-453
19. Accessory mitral valve tissue causing severe left ventricular outflow tract obstruction in an adult. Aoka Y, Ishizuka N, Sakomura Y, Nagashima H, Kawana M, Kawai A, Kasanuki H *Ann Thorac Surg*. 2004;77: 713-715
20. The status of lipid management in 1836 patients with coronary artery disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving low-density lipoprotein cholesterol goal targeted by Japan Atherosclerosis Society guidelines. Nagashima H, Kasanuki H. *J Atheroscler Thromb*. 2005;12:338-342
21. Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Sakurabayashi-Kitade S, Aoka Y, Nagashima H, Kasanuki H, Hagiwara N, Kawana

- M. *Atherosclerosis*. 2009;206:54-60
22. Improvement of cardiac function and neurological remodeling in a patient with tachycardia-induced cardiomyopathy after catheter ablation. Omichi C, Tanaka T, Kakizawa Y, Yamada A, Ishii Y, Nagashima H, Kanmatsuse K, Endo M. *J Cardiol*. 2009;54:134-138
 23. Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Nagashima H, Endo M. *Heart Vessels*. 2011; 26:428-434
 24. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C; Tanezumab Investigators. *Osteoarthritis Cartilage*. 2011;19:1405-1412
 25. Rivaroxaban vs. Warfarin in Japanese patients with atrial fibrillation -the J-ROCKET AF study- Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, J-ROCKET AF study investigators. *Circ J*. 2012;76:2104-2111
 26. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Saito K, Nagashima H, Noguchi K, Yoshisue K, Yokogawa T, Matsushima E, Tahara T, Takagi S. *Cancer Chemother Pharmacol*. 2014;73(3):577-83.
 27. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. 2014;370(18):1702-11.
 28. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo-controlled study. Osamu N, Hirotaka N, Koji S, Kenji T. *J Dermatol Sci*. 2014;75(3):201-4
 29. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects. Shiozaki T, Ueno T, Nagashima H, Yamahira N, Hiraoka M, Eley T, Bifano M, Bertz RJ. *Int J Clin Pharmacol Ther* 2015;53(4):292-302
 30. Pharmacokinetics, pharmacodynamics and population pharmacokinetic/pharmacodynamics modeling of Bilastine, a second-generation antihistamine, in healthy Japanese subjects. Togawa M, Yamaya H, Rodriguez M, Nagashima H. *Clin Drug Invest* 2016;36(12):1011-1021.

31. Optimizing a Single Monthly Dose of Risedronate Based on its Weekly Dose in Healthy Japanese Postmenopausal Women. *Jpn J Clin Pharmacol Ther* 2017;48(4): 121-129